Not Medicare Enrolled

Dr. Dania Wierzbicki, MD

Allergy & Immunology · Dallas, TX
Low-engagement
5499 GLEN LAKES DR, Dallas, TX 75231
2146911330
In practice since 2006 (19 years)
NPI: 1841222346 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Wierzbicki from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Wierzbicki? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Wierzbicki

Dr. Dania Wierzbicki is an allergy & immunology in Dallas, TX, with 19 years in practice.

Between the years covered by Open Payments, Dr. Wierzbicki received a total of $9,507 from 38 pharmaceutical and/or device companies across 452 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in allergy & immunology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Wierzbicki is Moderate — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice$ $9,507 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$9,507
Total received (2018-2024)
Avg $1,358/year across 7 years
Top 33% in TX for allergy & immunology
38
Companies
452
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,507 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,476
2023
$1,301
2022
$1,298
2021
$1,546
2020
$1,277
2019
$1,306
2018
$1,303

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$2,059
Regeneron Healthcare Solutions, Inc.
$1,160
GlaxoSmithKline, LLC.
$921
ALK-Abello, Inc
$651
GENZYME CORPORATION
$549
CSL Behring
$436
Takeda Pharmaceuticals U.S.A., Inc.
$364
Covis Pharma GmBH
$344
Teva Pharmaceuticals USA, Inc.
$293
Novartis Pharmaceuticals Corporation
$266
kaleo, Inc.
$255
Pharming Healthcare, Inc.
$250
Grifols USA, LLC
$240
Octapharma USA, Inc.
$214
Genentech USA, Inc.
$158
Shire North American Group Inc
$151
PFIZER INC.
$149
Covis Pharma B.V.
$136
Boehringer Ingelheim Pharmaceuticals, Inc.
$133
Covis Pharma GmbH
$115
LEO Pharma Inc.
$80
Amgen Inc.
$80
Incyte Corporation
$73
BioCryst US Sales Co., LLC
$58
Hikma Pharmaceuticals USA
$54
Blueprint Medicines Corporation
$38
HOSPIRA, INC.
$35
Optinose US, Inc.
$34
OptiNose US, Inc.
$31
BOSTON SCIENTIFIC CORPORATION
$25
AbbVie Inc.
$25
SANOFI-AVENTIS U.S. LLC
$25
BioCryst Pharmaceuticals, Inc.
$22
ABBVIE INC.
$19
Boston Scientific Corporation
$18
Mylan Specialty L.P.
$17
Sunovion Pharmaceuticals Inc.
$15
Almirall LLC
$12
Top 3 companies account for 43.5% of total payments
Associated products mentioned in payments ›
ADBRY · AIRSUPRA · ALVESCO · AUVI-Q · AYVAKIT · AirDuo Digihaler · BREO · BREZTRI · CINQAIR · CINRYZE · CUTAQUIG · CUVITRU · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dymista · EUCRISA · FASENRA · FIRAZYR · GENERAL - PAIN MANAGEMENT · GENERAL PAIN MANAGEMENT · Gamunex-C · Grastek · HYQVIA · Haegarda · Hizentra · NUCALA · OCTAGAM · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPZELURA · ORLADEYO · Odactra · Orladeyo · Otiprio · PRE-PEN · PREVNAR 20 · Privigen · ProAir Digihaler · QVAR · RINVOQ · RUCONEST · Ryaltris · SHINGRIX · SPIRIVA · SPIRIVA RESPIMAT · STANDARDIZED · STIOLTO RESPIMAT · SYMBICORT · TAKHZYRO · TEZSPIRE · TIMOTHY · TRELEGY ELLIPTA · Utibron · VERDESO · XOLAIR · Xembify · Xhance · Xolair
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a allergy & immunology in Dallas?
Compare allergy & immunologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse allergy & immunologys nearby

Geographic Context

Allergy & Immunologys within 10 mi
66
Per 100K population
2.5
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Wierzbicki is a allergy & immunology, and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Wierzbicki receive payments from pharmaceutical companies?
Yes. Dr. Wierzbicki received a total of $9,507 from 38 companies across 452 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Wierzbicki) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →